ltb

LTB is a prodrug formed through the conjugation of the glycolysis inhibitor (Lonidamine) and the PD1 PDL1 blocker (BMS-1) via a thioketal bond. LTB can encapsulate the photosensitizer Chlorin e6 (Ce6), constructing a co-delivery photodynamic nanoplatfform through self-assembly (LTB-6 NPs).

LTB4-IN-1 (Anti-inflammatory agent 2) with IC50 of 70 nM is an inhibitor of leukotriene synthesis (LTB4).

Compound 24e, a leukotriene B4 (LTB4) antagonist, exhibits an inhibitory concentration 50 (IC50) of 477 nM and demonstrates anti-inflammatory activity [1].

LTB4 Antagonist 1, a carboxamide-acid derivative, potently inhibits Leukotriene B4 (LTB4) activity with an IC50 value of 288 nM and exhibits notable anti-inflammatory properties [1].

LTB4-IN-2 (Compound 6x) is a selective inhibitor of Leukotriene B4 (LTB4), acting by specifically targeting the 5-Lipoxygenase-activating protein (FLAP) with an inhibitory concentration (IC 50) of 1.15 μM, thus serving as a potential agent for anti-inflammatory research [1].

LTB4 antagonist 2, a carboxamide-acid compound, serves as an antagonist to leukotriene B4 (LTB4) with potential anti-inflammatory properties, exhibiting high affinity for the LTB4 receptor and an inhibitory concentration (IC50) of 439 nM [1].

Bepotastine Besilate (TAU 284) is a non-sedating and selective H1 receptor antagonist (pIC50: 5.7).

Bepotastine (Bepotastine free base) free base is a histamine 1 (H1) receptor antagonis.

BIIL-260 hydrochloride is an orally active and highly efficient leukotriene B4 (LTB4) receptor antagonist with anti-inflammatory activity. It interacts with the LTB4 receptor in a saturable, reversible, and competitive manner, inhibiting LTB4-induced intracellular Ca2+ release in human neutrophils.

γ-Linolenic acid ethyl ester (Ethyl γ-linolenate) is a leukotriene B4 receptor 4 (LTB4) antagonist with potential anti-inflammatory effects[1].

Leukotriene B4 (LTB4) is a compound derived from arachidonic acid via the 5-lipoxygenase pathway that mediates certain inflammatory and immune responses. Leukotriene B4 induces neutrophil extracellular traps that impede the clearance of Pneumocystis japonicus.

LY255283 is a specific antagonit of leukotriene B4 (LTB4) receptor. It inhibits the production of LTB(4) in human peripheral blood polymorphonuclear leukocytes (PMNL) and in monocytes activated by calcium ionophore A23187.

Lon-TK is a glycolysis inhibitor of LTB, linked with a linker conjugate. LTB is an intelligent responsive prodrug, comprised of Lonidamine (Lon) and a PD-L1 inhibitor (BMS-1), which are connected through a thioketal linkage. It effectively inhibits glycolytic metabolism in tumor cells and blocks the PD-1 PD-L1 immune escape pathway. Lon-TK holds potential for use in photodynamic-enhanced immunotherapy research.